Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Sections
Biomarkers of Thyroid Cancer
share announcement

Biomarkers of Thyroid Cancer

A topical collection in Cancers (ISSN 2072-6694). This collection belongs to the section "Cancer Biomarkers".

Viewed by 2226

Editors

Prof. Dr. Chan-Kwon Jung

E-Mail Website
Collection Editor
Department of Pathology, Seoul St. Mary’s Hospital, The Catholic University, Seoul 06591, Republic of Korea
Interests: thyroid molecular pathology/histology/cytology; endocrine pathology; cancer biomarkers; genetics; bone and soft tissue pathology
Special Issues, Collections and Topics in MDPI journals
Dr. Andrey Bychkov

E-Mail Website
Collection Editor
Department of Pathology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan
Interests: thyroid cancer; thyroid pathology; cancer biomarkers
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

Thyroid cancer is a heterogeneous disease comprising various molecular and histologic subtypes. Its diverse clinical outcomes highlight the need for identifying robust biomarkers of practical relevance. Biomarkers provide useful information in guiding clinical decision making in patients with thyroid cancer. Biomarkers can be biomolecules such as DNA, RNA, protein, peptide, and biomolecule chemical modifications, or characteristics that can be measured through clinical, pathological, or radiological findings. Biomarkers for thyroid cancer patients are used in research and clinical practice for:

  • Diagnosing thyroid nodules and thyroid cancer;
  • Predicting outcomes of thyroid cancer;
  • Including responses to specific therapeutic interventions;
  • Targeting specific groups of patients for whom a particular drug may be useful.

This Collection of Cancers is aimed at presenting the latest research on the diagnostic, prognostic, and theranostic biomarkers of thyroid cancer, as well as the application of biomarkers in clinical trials.

Prof. Dr. Chan-Kwon Jung
Dr. Andrey Bychkov
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thyroid cancer
  • biomarkers
  • diagnosis
  • prognosis
  • treatment
  • outcome

Related Special Issue

Published Papers (2 papers)

Download All Papers

2024

Jump to: 2023

10 pages, 1219 KiB  
Article
Pre-Operative Calcitonin and CEA Values May Predict the Extent of Metastases to the Lateral Neck Lymph Nodes in Patients with Medullary Thyroid Cancer
by Antonio Prinzi, Francesco Frasca, Marco Russo, Gabriella Pellegriti, Tommaso Piticchio, Dario Tumino, Antonino Belfiore and Pasqualino Malandrino
Cancers 2024, 16(17), 2979; https://doi.org/10.3390/cancers16172979 - 27 Aug 2024
Viewed by 737
Abstract
Background: In medullary thyroid cancer (MTC), lymph node metastases are often present at diagnosis and the extent of surgery is usually based upon pre-operative calcitonin and CEA levels as well as ultrasound findings. The aim of this study was to evaluate the [...] Read more.
Background: In medullary thyroid cancer (MTC), lymph node metastases are often present at diagnosis and the extent of surgery is usually based upon pre-operative calcitonin and CEA levels as well as ultrasound findings. The aim of this study was to evaluate the role of pre-operative calcitonin and CEA levels as predictive markers of the burden of lymph node metastases at diagnosis. Methods: we conducted a retrospective study analyzing 87 MTC patients. Results: The median levels of calcitonin and CEA were 88.4 pg/mL and 7.0 ng/mL, respectively, in patients with no lymph nodes metastases; 108.0 pg/mL and 9.6 ng/mL, respectively, in patients with metastases to 1–5 lymph nodes; 520.5 pg/mL and 43.2 ng/mL, respectively, in patients with metastases to >5 lymph nodes. There were no significant differences in pre-operative calcitonin and CEA values between N0 and N1a patients, whereas they were significantly higher in N1b patients. Pre-operative cut-off levels distinguishing N0/N1a from N1b patients were 90 pg/mL for calcitonin (sensitivity 100%, specificity 59.3%, AUC = 0.82) and 17 ng/mL for CEA (sensitivity 100%, specificity 75%, AUC = 0.89). Conclusions: in patients with MTC, pre-operative serum calcitonin and CEA levels may drive the decision-making process to better define the extent of surgery. Full article
►▼ Show Figures

Figure 1

2023

Jump to: 2024

12 pages, 985 KiB  
Article
BRAFV600E Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
by Joonseon Park, Solji An, Kwangsoon Kim, Ja Seong Bae and Jeong Soo Kim
Cancers 2023, 15(22), 5395; https://doi.org/10.3390/cancers15225395 - 13 Nov 2023
Cited by 2 | Viewed by 1156
Abstract
BRAFV600E positivity is associated with increased aggressiveness of papillary thyroid cancer (PTC), and age is an important prognostic factor. However, the association between age and BRAFV600E positivity and the recurrence risk has not been investigated. This study aimed to investigate the [...] Read more.
BRAFV600E positivity is associated with increased aggressiveness of papillary thyroid cancer (PTC), and age is an important prognostic factor. However, the association between age and BRAFV600E positivity and the recurrence risk has not been investigated. This study aimed to investigate the impact of age on recurrence between patients with BRAFV600E-positive and -negative PTC. Patients with PTC who underwent initial thyroid surgery between January 2010 and December 2018 at Seoul St. Mary’s Hospital (Seoul, Republic of Korea) were retrospectively reviewed. The BRAFV600E-positive (n = 1768) and BRAFV600E-negative groups (n = 428) were divided into two subgroups: younger (<35 years) and older groups (≥55 years). In the BRAFV600E-positive group, the younger group exhibited higher lymphatic and vascular invasion rates, more positive lymph nodes, higher lymph node ratios, and higher recurrence rates than the older group (5.9% vs. 2.1%). Multivariate analysis revealed that age, lymphatic invasion, and N category were significant risk factors in the BRAFV600E-positive group. In the BRAFV600E-positive group, the younger group had a higher recurrence risk than the older group (OR, 2.528; 95% confidence interval, 1.443–4.430; p = 0.001). In the BRAFV600E-negative group, age had no impact on recurrence risk. These results contribute to tailored treatment strategies and informed patient management. Full article
►▼ Show Figures

Figure 1

Back to TopTop